BRPI0619620B1 - composição veterinária oral e uso da mesma - Google Patents
composição veterinária oral e uso da mesma Download PDFInfo
- Publication number
- BRPI0619620B1 BRPI0619620B1 BRPI0619620-9A BRPI0619620A BRPI0619620B1 BR PI0619620 B1 BRPI0619620 B1 BR PI0619620B1 BR PI0619620 A BRPI0619620 A BR PI0619620A BR PI0619620 B1 BRPI0619620 B1 BR PI0619620B1
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- benzimidazole
- macrocyclic lactone
- moxidectin
- triclabendazole
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 58
- 150000002596 lactones Chemical class 0.000 claims abstract description 22
- 241001465754 Metazoa Species 0.000 claims abstract description 18
- NQPDXQQQCQDHHW-UHFFFAOYSA-N 6-chloro-5-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzimidazole Chemical compound ClC=1C=C2NC(SC)=NC2=CC=1OC1=CC=CC(Cl)=C1Cl NQPDXQQQCQDHHW-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229960000323 triclabendazole Drugs 0.000 claims abstract description 15
- -1 benzimidazole compound Chemical class 0.000 claims abstract description 11
- 239000002904 solvent Substances 0.000 claims abstract description 11
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 239000004094 surface-active agent Substances 0.000 claims abstract description 9
- 208000015181 infectious disease Diseases 0.000 claims abstract description 7
- 230000000507 anthelmentic effect Effects 0.000 claims abstract 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 24
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims description 22
- YZBLFMPOMVTDJY-CBYMMZEQSA-N moxidectin Chemical compound O1[C@H](C(\C)=C\C(C)C)[C@@H](C)C(=N/OC)\C[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 YZBLFMPOMVTDJY-CBYMMZEQSA-N 0.000 claims description 16
- 229960004816 moxidectin Drugs 0.000 claims description 16
- 239000005660 Abamectin Substances 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 229960002669 albendazole Drugs 0.000 claims description 8
- HXHWSAZORRCQMX-UHFFFAOYSA-N albendazole Chemical compound CCCSC1=CC=C2NC(NC(=O)OC)=NC2=C1 HXHWSAZORRCQMX-UHFFFAOYSA-N 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 claims description 6
- IBSREHMXUMOFBB-JFUDTMANSA-N 5u8924t11h Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 IBSREHMXUMOFBB-JFUDTMANSA-N 0.000 claims description 6
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 claims description 6
- 206010061217 Infestation Diseases 0.000 claims description 6
- BWCRYQGQPDBOAU-UHFFFAOYSA-N Milbemycin D Natural products C1CC(C)C(C(C)C)OC21OC(CC=C(C)CC(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 BWCRYQGQPDBOAU-UHFFFAOYSA-N 0.000 claims description 6
- YRWLZFXJFBZBEY-UHFFFAOYSA-N N-(6-butyl-1H-benzimidazol-2-yl)carbamic acid methyl ester Chemical compound CCCCC1=CC=C2N=C(NC(=O)OC)NC2=C1 YRWLZFXJFBZBEY-UHFFFAOYSA-N 0.000 claims description 6
- RAOCRURYZCVHMG-UHFFFAOYSA-N N-(6-propoxy-1H-benzimidazol-2-yl)carbamic acid methyl ester Chemical compound CCCOC1=CC=C2N=C(NC(=O)OC)NC2=C1 RAOCRURYZCVHMG-UHFFFAOYSA-N 0.000 claims description 6
- 229950008167 abamectin Drugs 0.000 claims description 6
- RRZXIRBKKLTSOM-XPNPUAGNSA-N avermectin B1a Chemical compound C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 RRZXIRBKKLTSOM-XPNPUAGNSA-N 0.000 claims description 6
- 229960003475 cambendazole Drugs 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- QLFZZSKTJWDQOS-YDBLARSUSA-N doramectin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C3CCCCC3)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C QLFZZSKTJWDQOS-YDBLARSUSA-N 0.000 claims description 6
- 229960003997 doramectin Drugs 0.000 claims description 6
- 229960005473 fenbendazole Drugs 0.000 claims description 6
- 229960002418 ivermectin Drugs 0.000 claims description 6
- 229960003439 mebendazole Drugs 0.000 claims description 6
- BWCRYQGQPDBOAU-WZBVPYLGSA-N milbemycin D Chemical group C1C[C@H](C)[C@@H](C(C)C)O[C@@]21O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 BWCRYQGQPDBOAU-WZBVPYLGSA-N 0.000 claims description 6
- 229960004454 oxfendazole Drugs 0.000 claims description 6
- BEZZFPOZAYTVHN-UHFFFAOYSA-N oxfendazole Chemical compound C=1C=C2NC(NC(=O)OC)=NC2=CC=1S(=O)C1=CC=CC=C1 BEZZFPOZAYTVHN-UHFFFAOYSA-N 0.000 claims description 6
- 229950007337 parbendazole Drugs 0.000 claims description 6
- QZWHWHNCPFEXLL-UHFFFAOYSA-N propan-2-yl n-[2-(1,3-thiazol-4-yl)-3h-benzimidazol-5-yl]carbamate Chemical compound N1C2=CC(NC(=O)OC(C)C)=CC=C2N=C1C1=CSC=N1 QZWHWHNCPFEXLL-UHFFFAOYSA-N 0.000 claims description 6
- 229960004546 thiabendazole Drugs 0.000 claims description 6
- WJCNZQLZVWNLKY-UHFFFAOYSA-N thiabendazole Chemical group S1C=NC(C=2NC3=CC=CC=C3N=2)=C1 WJCNZQLZVWNLKY-UHFFFAOYSA-N 0.000 claims description 6
- 239000004308 thiabendazole Substances 0.000 claims description 6
- 235000010296 thiabendazole Nutrition 0.000 claims description 6
- HMCCXLBXIJMERM-UHFFFAOYSA-N Febantel Chemical compound C1=C(NC(NC(=O)OC)=NC(=O)OC)C(NC(=O)COC)=CC(SC=2C=CC=CC=2)=C1 HMCCXLBXIJMERM-UHFFFAOYSA-N 0.000 claims description 5
- VXTGHWHFYNYFFV-UHFFFAOYSA-N albendazole S-oxide Chemical compound CCCS(=O)C1=CC=C2NC(NC(=O)OC)=NC2=C1 VXTGHWHFYNYFFV-UHFFFAOYSA-N 0.000 claims description 5
- 229950010075 albendazole sulfoxide Drugs 0.000 claims description 5
- YFNCATAIYKQPOO-UHFFFAOYSA-N thiophanate Chemical compound CCOC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OCC YFNCATAIYKQPOO-UHFFFAOYSA-N 0.000 claims description 5
- WCBVUETZRWGIJQ-UHFFFAOYSA-N 2-[[(methoxycarbonylamino)-(2-nitro-5-propylsulfanylanilino)methylidene]amino]ethanesulfonic acid Chemical compound CCCSC1=CC=C([N+]([O-])=O)C(NC(NC(=O)OC)=NCCS(O)(=O)=O)=C1 WCBVUETZRWGIJQ-UHFFFAOYSA-N 0.000 claims description 4
- 241000283086 Equidae Species 0.000 claims description 4
- 241001494479 Pecora Species 0.000 claims description 4
- 229960005282 febantel Drugs 0.000 claims description 4
- 241000283690 Bos taurus Species 0.000 claims description 3
- 241000282898 Sus scrofa Species 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000003304 gavage Methods 0.000 claims description 2
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- IRHZVMHXVHSMKB-UHFFFAOYSA-N fenbendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1SC1=CC=CC=C1 IRHZVMHXVHSMKB-UHFFFAOYSA-N 0.000 claims 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 2
- BAXLBXFAUKGCDY-UHFFFAOYSA-N mebendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CC=C1 BAXLBXFAUKGCDY-UHFFFAOYSA-N 0.000 claims 2
- 229920001515 polyalkylene glycol Polymers 0.000 claims 2
- YEYKMVJDLWJFOA-UHFFFAOYSA-N 2-propoxyethanol Chemical compound CCCOCCO YEYKMVJDLWJFOA-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229950006716 netobimin Drugs 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 13
- 206010014143 Ectoparasitic Infestations Diseases 0.000 abstract 2
- 239000000243 solution Substances 0.000 description 10
- 150000001556 benzimidazoles Chemical class 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 239000003921 oil Substances 0.000 description 7
- 244000045947 parasite Species 0.000 description 5
- HDDSHPAODJUKPD-UHFFFAOYSA-N fenbendazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1SC1=CC=CC=C1 HDDSHPAODJUKPD-UHFFFAOYSA-N 0.000 description 4
- OPXLLQIJSORQAM-UHFFFAOYSA-N mebendazole Chemical compound C=1C=C2NC(NC(=O)OC)=NC2=CC=1C(=O)C1=CC=CC=C1 OPXLLQIJSORQAM-UHFFFAOYSA-N 0.000 description 4
- 230000000590 parasiticidal effect Effects 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 244000078703 ectoparasite Species 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000012456 homogeneous solution Substances 0.000 description 3
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000244206 Nematoda Species 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- 241000242541 Trematoda Species 0.000 description 2
- KGUHOFWIXKIURA-VQXBOQCVSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl dodecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCC)O[C@@H]1O[C@@]1(CO)[C@@H](O)[C@H](O)[C@@H](CO)O1 KGUHOFWIXKIURA-VQXBOQCVSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000001984 ectoparasiticidal effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- FXWHFKOXMBTCMP-WMEDONTMSA-N milbemycin Chemical class COC1C2OCC3=C/C=C/C(C)CC(=CCC4CC(CC5(O4)OC(C)C(C)C(OC(=O)C(C)CC(C)C)C5O)OC(=O)C(C=C1C)C23O)C FXWHFKOXMBTCMP-WMEDONTMSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940032085 sucrose monolaurate Drugs 0.000 description 2
- RFEJUZJILGIRHQ-XRIOVQLTSA-N 2,3-dihydroxybutanedioic acid;3-[(2s)-1-methylpyrrolidin-2-yl]pyridine Chemical compound OC(=O)C(O)C(O)C(O)=O.OC(=O)C(O)C(O)C(O)=O.CN1CCC[C@H]1C1=CC=CN=C1 RFEJUZJILGIRHQ-XRIOVQLTSA-N 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000283014 Dama Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 241000283011 Rangifer Species 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000009418 agronomic effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000013057 ectoparasiticide Substances 0.000 description 1
- 244000079386 endoparasite Species 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 229940072106 hydroxystearate Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- ZLBGSRMUSVULIE-GSMJGMFJSA-N milbemycin A3 Chemical class O1[C@H](C)[C@@H](C)CC[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 ZLBGSRMUSVULIE-GSMJGMFJSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74272405P | 2005-12-06 | 2005-12-06 | |
| US742,724 | 2005-12-06 | ||
| PCT/US2006/046197 WO2007067470A2 (en) | 2005-12-06 | 2006-12-04 | Benzimidazole non-aqueous compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0619620A2 BRPI0619620A2 (pt) | 2011-10-04 |
| BRPI0619620B1 true BRPI0619620B1 (pt) | 2020-11-10 |
Family
ID=37903547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0619620-9A BRPI0619620B1 (pt) | 2005-12-06 | 2006-12-04 | composição veterinária oral e uso da mesma |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7687471B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1957040B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5342239B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20080073700A (cg-RX-API-DMAC7.html) |
| AR (1) | AR057219A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006322120B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0619620B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2630458C (cg-RX-API-DMAC7.html) |
| DK (1) | DK1957040T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2527120T3 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ567991A (cg-RX-API-DMAC7.html) |
| PT (1) | PT1957040E (cg-RX-API-DMAC7.html) |
| TW (1) | TWI433691B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2007067470A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200804915B (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101403135B1 (ko) | 2006-06-14 | 2014-06-19 | 인터벳 인터내셔널 비.브이. | 벤지미다졸 카르바메이트 및 폴리솔베이트를 포함하는 현탁물 |
| TWI556741B (zh) | 2007-08-17 | 2016-11-11 | 英特威特國際股份有限公司 | 異唑啉組成物及其作為抗寄生蟲藥上的應用 |
| RU2493825C2 (ru) * | 2008-10-08 | 2013-09-27 | ВАЙЕТ ЭлЭлСи | Бензимидазольные антигельминтные композиции |
| WO2010126857A1 (en) * | 2009-04-28 | 2010-11-04 | Wyeth Llc | Parasiticidal combinations of macrocyclic lactones and polyether antibiotics |
| CN104619345A (zh) * | 2012-05-18 | 2015-05-13 | 罗达制药有限公司 | 液体制剂 |
| BR102013031277B1 (pt) * | 2013-12-05 | 2018-10-02 | Ouro Fino Participacoes E Empreendimentos S A | processo para preparar uma suspensão anti-helmíntica e suspensão anti-helmíntica injetável |
| CN112006981B (zh) * | 2020-07-30 | 2023-01-10 | 瑞普（天津）生物药业有限公司 | 一种长效复方驱虫药物液体制剂及其制备方法与应用 |
| AU2021335500A1 (en) | 2020-09-04 | 2023-05-04 | Elanco Us Inc. | Palatable formulations |
| BR102020021181A2 (pt) * | 2020-10-16 | 2022-04-26 | Ipanema Industria De Produtos Veterinarios Ltda | Microssuspensão contra parasitas e método para sua obtenção |
| CN114304161B (zh) * | 2021-11-25 | 2024-08-09 | 兰州大学 | 三氯苯达唑在防治农业病原菌中的用途 |
| WO2025221973A1 (en) * | 2024-04-18 | 2025-10-23 | Jjr&D, Llc | Topical benzimidazole formulations and methods for use in treating inflammatory dermatoses |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994027598A1 (en) | 1993-05-26 | 1994-12-08 | Commonwealth Scientific And Industrial Research Organisation | Antiparasitic compositions |
| FR2755824B1 (fr) * | 1996-11-19 | 1999-01-08 | Virbac Sa | Formulation galenique des benzimidazoles a usage topique, son procede de preparation et ses utilisations |
| US6267985B1 (en) * | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| ATE313952T1 (de) * | 1999-06-04 | 2006-01-15 | Nufarm Ltd | Stabile biozidale zusammensetzung |
| NZ515772A (en) * | 1999-06-04 | 2002-12-20 | Nufarm Ltd | Pesticidal emulsion composition containing levamisole in the aqueous phase and an anthelmintic in the organic phase |
| CN1435176A (zh) | 2002-01-29 | 2003-08-13 | 王玉万 | 以表面活性剂为基础的含三氯苯哒唑的新制剂 |
| AU2002952597A0 (en) * | 2002-11-11 | 2002-11-28 | Schering-Plough Pty. Limited | Topical parasiticide formulations and methods of treatment |
| WO2005074914A1 (en) * | 2004-02-03 | 2005-08-18 | Wyeth | Anthelmintic composition |
-
2006
- 2006-12-04 EP EP06838906.3A patent/EP1957040B1/en active Active
- 2006-12-04 DK DK06838906.3T patent/DK1957040T3/en active
- 2006-12-04 AU AU2006322120A patent/AU2006322120B2/en active Active
- 2006-12-04 PT PT68389063T patent/PT1957040E/pt unknown
- 2006-12-04 KR KR1020087009605A patent/KR20080073700A/ko not_active Ceased
- 2006-12-04 ES ES06838906.3T patent/ES2527120T3/es active Active
- 2006-12-04 NZ NZ567991A patent/NZ567991A/en unknown
- 2006-12-04 BR BRPI0619620-9A patent/BRPI0619620B1/pt active IP Right Grant
- 2006-12-04 JP JP2008544409A patent/JP5342239B2/ja not_active Expired - Fee Related
- 2006-12-04 AR ARP060105354A patent/AR057219A1/es not_active Application Discontinuation
- 2006-12-04 WO PCT/US2006/046197 patent/WO2007067470A2/en not_active Ceased
- 2006-12-04 CA CA2630458A patent/CA2630458C/en not_active Expired - Fee Related
- 2006-12-05 US US11/634,027 patent/US7687471B2/en not_active Expired - Fee Related
- 2006-12-06 TW TW095145431A patent/TWI433691B/zh not_active IP Right Cessation
-
2008
- 2008-06-05 ZA ZA200804915A patent/ZA200804915B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2630458C (en) | 2014-10-28 |
| NZ567991A (en) | 2010-07-30 |
| KR20080073700A (ko) | 2008-08-11 |
| BRPI0619620A2 (pt) | 2011-10-04 |
| ES2527120T3 (es) | 2015-01-20 |
| AR057219A1 (es) | 2007-11-21 |
| WO2007067470A2 (en) | 2007-06-14 |
| TWI433691B (zh) | 2014-04-11 |
| US7687471B2 (en) | 2010-03-30 |
| AU2006322120A1 (en) | 2007-06-14 |
| PT1957040E (pt) | 2015-01-14 |
| ZA200804915B (en) | 2010-08-25 |
| AU2006322120B2 (en) | 2012-07-26 |
| EP1957040A2 (en) | 2008-08-20 |
| TW200800293A (en) | 2008-01-01 |
| JP2009518400A (ja) | 2009-05-07 |
| DK1957040T3 (en) | 2014-12-08 |
| WO2007067470A3 (en) | 2007-10-18 |
| US20070128239A1 (en) | 2007-06-07 |
| JP5342239B2 (ja) | 2013-11-13 |
| CA2630458A1 (en) | 2007-06-14 |
| EP1957040B1 (en) | 2014-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5319691B2 (ja) | プラジカンテル、マクロライドラクトン、シクロデキストリンおよび粘稠化剤を含む駆虫ペースト | |
| JP2005533806A (ja) | 駆虫性動物用均質経口ペースト | |
| BR0307974B1 (pt) | composição parasiticida de ação prolongada contendo um composto de salicilanilida, uma espécie polimérica e pelo menos um outro composto antiparasita | |
| BRPI0312814B1 (pt) | levamisol / avermectinas ou similares em solvente de pirrolidona | |
| JP5342239B2 (ja) | ベンジイミダゾール非水性組成物 | |
| AU2011268899B2 (en) | Injectable formulation of a macrocyclic lactone and levamisole | |
| BR112013002177B1 (pt) | Composição de uma droga veterinária para uso no controle de infestações por verme do coração em uma cobaia animal não humana, e kit para tratamento e/ou prevenção deinfestação parasitária por verme do coração em uma cobaia animal não humana | |
| EP1259244B1 (en) | Veterinary compositions for the treatment of parasitic diseases | |
| WO2008077130A2 (en) | Homogeneous paste and gel formulations | |
| AU2001235489A1 (en) | Veterinary compositions for the treatment of parasitic diseases | |
| EP1503733B1 (fr) | Compositions orales huileuses antiparasitaires | |
| CN1166676C (zh) | 可注射的驱虫制剂 | |
| AU2007100254B4 (en) | Improved parasiticide paste | |
| CN104983680A (zh) | 一种羊用复方驱虫药的稳定性纳米悬浮制剂及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved |
Owner name: WYETH LLC (US) |
|
| B25A | Requested transfer of rights approved |
Owner name: PAH W LLC (US) |
|
| B25D | Requested change of name of applicant approved |
Owner name: ZOETIS W LLC (US) |
|
| B25A | Requested transfer of rights approved |
Owner name: ZOETIS SERVICES LLC (US) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI. |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.21 NA RPI NO 2538 DE 27/08/2019 POR TER SIDO INDEVIDA. |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/11/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B25G | Requested change of headquarter approved |
Owner name: ZOETIS SERVICES LLC (US) |